Literature DB >> 23534808

Diagnostic role of survivin in urinary bladder cancer.

Anupam Kumar Srivastava1, Pankaj Kumar Singh, Kirti Srivastava, Dhramveer Singh, Divakar Dalela, Srikanta Kumar Rath, Madhu Mati Goel, Madan Lal Brahma Bhatt.   

Abstract

BACKGROUND: Early diagnosis of carcinoma of bladder remains a challenge. Survivin, a member of the inhibitor of apoptosis (IAP) protein family, is frequently activated in bladder carcinoma. The objective of this study was to investigate urinary survivin as a marker for diagnosis of urinary bladder.
MATERIALS AND METHODS: We examined urinary survivin concentration in 28 healthy individuals, 46 positive controls and 117 cases of histologically proven TCC prior to transurethral resection, using ELISA, and compared values with findings for urinary cytology.
RESULTS: Survivin was found to be significantly higher in the cancer group (P<0.05). A cut off value of 17.7 pg/ml was proposed, with an approximate sensitivity of 82.9% and specificity of 81.1% (P<0.0001), whereas urine cytology had a sensitivity of 66.7% and a specificity of 96.0%.
CONCLUSIONS: Urinary survivin can be used as a non-invasive diagnostic biomarker for TCC bladder, both for primary and recurrent disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23534808     DOI: 10.7314/apjcp.2013.14.1.81

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  19 in total

1.  Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder.

Authors:  A K Srivastava; P K Singh; D Singh; D Dalela; S K Rath; M M Goel; M L B Bhatt
Journal:  Tumour Biol       Date:  2014-05-23

2.  Diagnostic value of urinary survivin as a biomarker for bladder cancer: a systematic review and meta-analysis of published studies.

Authors:  Zhenzhen Liang; Rui Xin; Yinghui Yu; Rui Wang; Chunpeng Wang; Xin Liu
Journal:  World J Urol       Date:  2018-04-02       Impact factor: 4.226

3.  Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: a comparative immunohistochemical study.

Authors:  Rania Makboul; Abeer E L-Refaiy M Refaiy; Fatma Ahmed Mahmoud Badary; Islam F Abdelkawi; Axel S Merseburger; Rabab Ahmed Ahmed Mohammed
Journal:  Korean J Urol       Date:  2015-01-08

4.  Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis.

Authors:  Aiye Guo; Xiuhua Wang; Lan Gao; Juan Shi; Changyi Sun; Zhen Wan
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

5.  Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer.

Authors:  Dana Vu Van; Ulrike Heberling; Manfred P Wirth; Susanne Fuessel
Journal:  Oncol Lett       Date:  2016-08-23       Impact factor: 2.967

6.  Performance of urinary survivin as a non-invasive molecular marker of bladdercarcinoma in a schistosomiasis endemic area.

Authors:  Abubakar S Muhammad; Ismaila A Mungadi; Enemeka D Ndodu; Garba D Kalayi
Journal:  Ghana Med J       Date:  2018-06

Review 7.  Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise.

Authors:  Fadi Darwiche; Dipen J Parekh; Mark L Gonzalgo
Journal:  Indian J Urol       Date:  2015 Oct-Dec

8.  Clinical significance of survivin expression in patients with urothelial carcinoma.

Authors:  Hsin-An Chen; Chih-Ming Su; Hsiao-Yen Hsieh; Chun-Liang Tung; Cheng-Da Hsu; Yuan-Hung Wang; Cheng-Huang Shen
Journal:  Dis Markers       Date:  2014-02-05       Impact factor: 3.434

9.  Sphingosine 1-phosphate interacts with Survivin pathway to enhance tumorigenesis in cancer cells.

Authors:  Maryam Tabasinezhad; Hamid Ghaedi; Parisa Qanbari; Mahsa Mohseni; Mehdi Sabzichi; Nasser Samadi
Journal:  Iran J Basic Med Sci       Date:  2015-08       Impact factor: 2.699

10.  A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer.

Authors:  Jamie J D'Costa; James C Goldsmith; Jayne S Wilson; Richard T Bryan; Douglas G Ward
Journal:  Bladder Cancer       Date:  2016-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.